Epidemiology of Clostridium difficile infection

Journal of Pharmacy Practice

Volumn 26, Issue 5, 2013, Pages 464-475

  Depestel, Daryl D ^a   Aronoff, David M ^b  

^a Medical Affairs   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Clostridium difficile; elderly; epidemiology; ribotype 027; risk factors

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; METRONIDAZOLE; NAVELBINE; PACLITAXEL; TOPOTECAN; VANCOMYCIN;

ANTIMICROBIAL ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE SEVERITY; EUROPE; HUMAN; LONG TERM CARE; MOLECULAR EPIDEMIOLOGY; MORBIDITY; MORTALITY; NONHUMAN; RECURRENT DISEASE; UNITED STATES;

CLOSTRIDIUM DIFFICILE; ELDERLY; EPIDEMIOLOGY; RIBOTYPE 027; RISK FACTORS;

ANIMALS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COST OF ILLNESS; EUROPE; HUMANS; INCIDENCE; MOLECULAR EPIDEMIOLOGY; POPULATION SURVEILLANCE; RECURRENCE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 84884690867     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190013499521     Document Type: Article

References (121)

1. Bartlett JG, Chang TW, Gurwith M, et al. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med. 1978 ; 298 (10). 531-534
2. Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis. 2008 ; 46 (suppl 1). S12 - S18
3. Kim J, Smathers SA, Prasad P, et al. Epidemiological features of Clostridium difficile-associated disease among inpatients at children's hospitals in the United States, 2001-2006. Pediatrics. 2008 ; 122 (6). 1266-1270
4. Surveillance for community-associated Clostridium difficile - connecticut, 2006. MMWR Morb Mortal Wkly Rep. 2008 ; 57 (13). 340-343
5. Wilcox MH, Mooney L, Bendall R, et al. A case-controlled study of community-associated Clostridium difficile infection. J Antimicrob Chemother. 2008 ; 62 (2). 388-396
6. Severe Clostridium difficile-associated disease in populations previously at low risk-four states, 2005. MMWR Morb Mortal Wkly Rep. 2005 ; 54 (47). 1201-1205
7. LucadoJGouldCElixhauserA.Clostridium difficile infections (CDI) in hospital stays, 2009. Healthcare cost and utilization project, agency for healthcare research and quality. Statistical brief #124. http://www.hcup-us. ahrq.gov/reports/statbriefs/sb124.pdf. Accessed January 8, 2013.
8. McDonald LC, Owings M, Jernigan DB.. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis. 2006 ; 12 (3). 409-415
9. Freeman J, Bauer MP, Baines SD, et al. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev. 2010 ; 23 (3). 529-549
10. ElixhauserA, Jhung MA. Clostridium difficile-associated disease in U.S. hospitals, 1993-2005. Healthcare cost and utilization project, agency for healthcare research and quality. Statistical brief #50. http://www.hcup-us.ahrq. gov/reports/statbriefs/sb50.pdf. Accessed January 8, 2013.
11. Miller BA, Chen LF, Sexton DJ, et al. Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol. 2011 ; 32 (4). 387-390
12. Zilberberg MD, Shorr AF, Kollef MH. Growth and geographic variation in hospitalizations with resistant infections, United States, 2000-2005. Emerg Infect Dis. 2008 ; 14 (11). 1756-1758
13. Warny M, Pépin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005 ; 366 (9491). 1079-1084
14. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005 ; 353 (23). 2433-2441
15. Pépin JL, Valiquette ME, Clossette B. Mortality attributed to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hyperviluent strain in Quebec. CMAJ. 2005 ; 173 (9). 1037-1042
16. Pépin JL, Valiquette ME, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991-2003: a changing pattern disease severity. CMAJ. 2004 ; 171 (5). 466-472
17. Muto CA, Pokrywka M, Shutt K, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol. 2005 ; 26 (3). 273-280
18. Goorhuis A, Van deer Kooi T, Vaessen N, et al. Spread and epidemiology of Clostridium difficile polymerase chain reaction ribotype 027/toxinotype III in The Netherlands. Clin Infect Dis. 2007 ; 45 (6). 695-703
19. Goorhuis A, Bakker D, Corver J, et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis. 2008 ; 47 (9). 1162-1170
20. Bauer MP, Notermans DW, van Benthem BH, et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet. 2011 ; 377 (9759). 63-73
21. Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis. 2012 ; 55 (suppl 2). S88 - S92
22. Finney JMT. Gastro-enterostomy for cicatrizing ulcer of the pylorus. Bull Johns Hopkins Hosp. 1893 ; 4: 53
23. Hall IC, O'Toole E. Intestinal flora in new-born infants: with a description of a new pathogenic anaerobe, Bacillus difficilis. Am J Dis Child. 1935 ; 49 (2). 390-402
24. Rosseau C, Poilane I, De Pontual LC, et al. Clostridium difficile carriage in healthy infants in the community: a potential reservoir for pathogenic strains. Clin Infect Dis. 2012 ; 55 (9). 1209-1215
25. Loo VG, Poirier L, Miller M, et al. A predominately clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005 ; 353 (23). 2442-2449
26. Altemeier WA, Hummel RP, Hill EO.. Staphylococcal enterocolitis following antibiotic therapy. Ann Surg. 1963 ; 157: 847-858
27. Tedesco FJ, Barton RW, Alpers DH. Clindamycin-associated colitis. A prospective study. Ann Intern Med. 1974 ; 81 (4). 429-433
28. Bartlett JG, Onderonk AB, Cisneros RL. Clindamycin-associated colitis in hamsters: protection with vancomycin. Gasterenterology. 1977 ; 73 (4 pt 1). 772-776
29. Rifkin GD, Fekety FR, Silva J. Antibiotic-induced colitis implication of a toxin neutralized by Clostridium sordellii antitoxin. Lancet. 1977 ; 2 (8048). 1103-1106
30. Larson HE, Price AB. Pseudomembranous colitis: presence of clostridial toxin. Lancet. 1977 ; 2 (8052-8053). 1312-1314
31. George WL, Sutter VL, Goldstein EJ, et al. Etiology of antimicrobial-agent-associated colitis. Lancet. 1978 ; 1 (8068). 802-803
32. Larson HE, Price AB, Honour P, et al. Clostridium difficile and the etiololgy of pseudomembranous colitis. Lancet. 1978 ; 1 (8073). 1063-1066
33. Gerding DN. Clostridium difficile 30 years on: what has, or has not, changed and why?. Int J Antimicrob Agents. 2009 ; 33 (suppl 1). S2 - S8
34. Redelings MD, Sorvillo F, Mascola L. Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg Infect Dis. 2007 ; 13 (9). 1417-1419
35. Kazakova SV, Ware K, Baughman B, et al. A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile. Arch Intern Med. 2006 ; 166 (22). 2518-2524
36. Labbé AC, Poirier L, MacCannell D, et al. Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain. Antimicrob Agents Chemother. 2008 ; 52 (9). 3180-2187
37. Smith A.. Outbreak of Clostridium difficile infection in an English hospital linked to hypertoxin-producing strains in Canada and the U.S. Eur Surveill. 2005 ; 10 (6). E050630
38. Kuijper EJ, van den Berg RJ, Debast S, et al. Clostridium difficile ribotype 027, toxinotype III, the Netherland. Emerg Infect Dis. 2006 ; 12 (5). 827-830
39. Kuijper EJ, Coignard B, Tüll P, et al. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect. 2006 ; 12 (suppl 6). 2-18
40. ElixhauserASteinerCGouldC. Readmissions following hospitalizations with Clostridium difficile infections, 2009. Healthcare cost and utilization project, agency for healthcare research and quality. Statistical brief #145. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb145.pdf. Accessed January 8, 2013.
41. Wilcox MH, Shetty N, Fawley WN, et al. Changing epidemiology of Clostridium difficile infection following the introduction of a national ribotyping-based surveillance scheme in England. Clin Infect Dis. 2012 ; 55 (8). 1056-1063
42. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society of healthcare epidemiology of America (SHEA) and the infectious diseases society of america (IDSA). Infect Control Hosp Epidemiol. 2010 ; 31 (5). 431-455
43. MiniñoAMXuJQKochanekKD. Deaths: preliminary data for 2008. National Vital Statistics Reports. Hyattsville, MD: National Center for Health Statistics; 2010;59. http://www.cdc.gov/nchs/data/nvsr/nvsr59/nvsr59-02.pdf. Accessed February 22, 2013.
44. Lessa FC, Gould CV, McDonald LC. Current status of Clostridium difficile infection epidemiology. Clin Infect Dis. 2012 ; 55 (suppl 2). S65 - S70
45. Khanna S, Pardi DS, Aronson SL, et al. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol. 2012 ; 107 (1). 89-95
46. Lessa FC. Community-associated Clostridium difficile infection: How real is it? [published online February 8, 2013]. Anaerobe. 2013 ;:
47. Nylund CM, Goudie A, Garza JM, et al. Clostridium difficile infection in hospitalized children in the United States. Arch Pediatr Adolesc Med. 2011 ; 165 (5). 451-457
48. Zilberberg MD, Tillotson GS, McDonald C.. Clostridium difficile infections among hospitalized children, United States, 1997-2006. Emerg Infect Dis. 2010 ; 16 (4). 604-609
49. Khanna S, Baddour LM, Huskins WC, et al. The epidemiology of Clostridium difficile infection in children: a population-based study. Clin Infect Dis. 2013 ; 56 (10). 1401-1406
50. McDonald LC, Lessa F, Sievert D, et al. Vital Signs: preventing Clostridium difficile infections. MMWR Morb Mortal Wkly Rep. 2012 ; 61 (9). 157-162
51. Campbell RJ, Giljahn L, Machesky K, et al. Clostridium difficile infection in Ohio hospitals and nursing homes during 2006. Infect Control Hosp Epidemiol. 2009 ; 30 (6). 526-533
52. Oake N, Taljaard M, van Walraven C, et al. The effect of hospital-acquired Clostridium difficile infection on in-hospital mortality. Arch Intern Med. 2010 ; 170 (20). 1804-1810
53. Dallal RM, Harbrecht BG, Boujoukas AJ, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg. 2002 ; 235 (3). 363-372
54. Kasper AM, Nyazee HA, Yokoe DS, et al. A multicenter study of Clostridium difficile infection-related colectomy, 2000-2006. Infect Control Hosp Epidemiol. 2012 ; 33 (5). 470-476
55. Gravel D, Miller M, Simor A, et al. Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian nosocomial infection surveillance program study. Clin Infect Dis. 2009 ; 48 (5). 568-576
56. Hubert B, Loo VG, Bourgault AM, et al. A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of Clostridium difficile-associated disease in Quebec. Clin Infect Dis. 2007 ; 44 (2). 238-244
57. Hall AJ, Curns AT, McDonald LC, et al. The roles of Clostridium difficile and norovirus among gastroenteritis-associated deaths in the United States, 1999-2007. Clin Infect Dis. 2012 ; 55 (2). 216-223
58. Hensgens MP, Goorhuis A, Dekkers OM, et al. All-cause and disease specific mortality in hospitalized patients with Clostridium difficile infection: a multicenter cohort study. Clin Infect Dis. 2013 ; 56 (8). 1108-1116
59. Black SR, Weaver KN, Jones RC, et al. Clostridium difficile outbreak strain BI is highly endemic in Chicago area hospitals. Infect Control Hosp Epidemiol. 2011 ; 32 (9). 897-902
60. Barbut F. Rupnik M. 027, 078, and others: going beyond the numbers (and away from the hypervirulence). Clin Infect Dis. 2012 ; 55 (12). 1669-1672
61. Rupnik M, Wilcox MH, Gerding DN.. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat. Rev Microbiol. 2009 ; 7 (7). 526-536
62. Walk ST, Micic D, Jain R, et al. Clostridium difficile ribotype does not predict severe infection. Clin Infect Dis. 2012 ; 55 (12). 1661-1668
63. McDonald LC. Virulence and clinical outcomes in Clostridium difficile infection: a complex business. Clin Infect Dis. 2012 ; 56 (6). 906-907
64. Walker AS, Eyre DW, Crook DW, et al. Response to Walk et al "Clostridium difficile ribotype does not predict severe infection". Clin Infect Dis. 2013 ; 56 (12). 1845-1846
65. Walk ST, Micic D, Galecki AT, et al. Reply to Walker et al. Clin Infect Dis. 2013 ; 56 (12). 1846-1847
66. O'Connor JR, Johnson S, Gerding DN.. Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastrenterology. 2009 ; 136 (6). 1913-1924
67. McFarland LV. Alternative treatments for Clostridium difficile disease: what really works?. J Med Microbiol. 2005 ; 54 (pt 2). 101-111
68. van Nood E, Speelman P, Kuijper EJ, et al. Struggling with recurrent Clostridium difficile infections: is donor faeces the solution?. Euro Surveill. 2009 ; 14 ( 34 ):
69. Kelly CP. Can we identify patients at high risk of recurrent Clostridium difficile infection?. Clin Microbiol Infec. 2012 ; 18 (suppl 6). 21-27
70. Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect. 2009 ; 58 (6). 403-410
71. Drekonja DM, Amundson WH, DeCarolis DD, et al. Antimicrobial use and risk for recurrent Clostridium difficile infection. Am J Med. 2011 ; 124 (11). e1-1081
72. Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis. 2008 ; 197 (3). 435-438
73. Garey KW, Sethi S, Yadav Y, et al. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect. 2008 ; 70 (4). 298-304
74. Didelot X, Eyre D, Cule M, et al. Microevolutionary analysis of Clostridium difficile genomes to investigate transmission. Genome Biol. 2012 ; 13 (12). R118
75. Pacheco SM, Johnson S. Important clinical advances in the understanding of Clostridium difficile infection. Curr Opin Gastroenterol. 2013 ; 29 (1). 42-48
76. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med. 1994 ; 330: 257
77. Mullane KM, Miller MA, Weiss K, et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis. 2011 ; 53 (5). 440-447
78. Tannock GW, Munro K, Taylor C, et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alterations to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology. 2010 ; 156 (pt 11). 3354-3359
79. Hensgens MP, Goorhuis A, Dekkers OM, et al. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother. 2012 ; 67 (3). 742-748
80. Stevens V, Dumyati G, Fine LS, et al. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis. 2011 ; 53 (1). 42-48
81. Johnson S, Samore MH, Farrow KA, et al. Epidemics of diarrhea caused by a clindamycin-resistance strain of Clostridium difficile in four hospitals. N Engl J Med. 1999 ; 341 (22). 1645-1651
82. Carignan A, Allard C, Pépin J, et al. Risk of Clostridium difficile infection after perioperative antibacterial prophylaxis before and during an outbreak of infection due to a hypervirulent strain. Clin Infect Dis. 2008 ; 46 (12). 1838-1843
83. Kuntz JL, Yang M, Cavanaugh J, et al. Trend in Clostridium difficile infection among peripartum women. Infect Control Hosp Epidemiol. 2010 ; 31 (5). 532-534
84. Shaughnessy MK, Amundson WH, Kuskowski MA, et al. Unnecessary antimicrobial use in patients with current or recent Clostridium difficile infection. Infect Control Hosp Epidemiol. 2013 ; 34 (2). 109-116
85. Janarthanan S, Ditah I, Adler DG, et al. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol. 2012 ; 107 (7). 1001-1010
86. Kwok CS, Arthur AK, Anibueze CI, et al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol. 2012 ; 107 (7). 1011-1019
87. United States Department of Health and Human Services. FDA Drug Safety Communication: Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs). http://www.fda.gov/ drugs/drugsafety/ucm290510.htm. Accessed February 20, 2013.
88. Thorens J, Froehlich F, Schwizer W, et al. Bacterial overgrowth during treatment with omperazole compared with cimetidine: a prospective randomized double blind study. Gut. 1996 ; 39 (1). 54-59
89. Jump RL, Pultz MJ, Donskey CJ.. Vegatative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidity: a potential mechanism to explain the association between proton pump inhibitors and C. difficile-associated diarrhea?. Antimicrob Agents Chemother. 2007 ; 51 (8). 2883-2887
90. Williams C. Occurrence and significance of gastric colonization during acid-inhibitory therapy. Best Pract Res Clin Gastroenterol. 2001 ; 15 (3). 511-521
91. Wilson KH, Sheagren JN, Freter R.. Population dynamics of ingested Clostridium difficile in the gastrointestinal tract of the Syrian hamster. J Infect Dis. 1985 ; 151 (2). 355-361
92. Agastya G, West BC, Callahan JM. Omperazole inhibits phagocytosis and acidification of phagolysosomes of normal human neutrophils in vitro. Immunopharmacol Immunotoxicol. 2000 ; 22 (2). 357-372
93. Yoshida N, Yoshikawa T, Tanaka Y, et al. A new mechanism for anti-inflammatory actions of proton pump inhibitors - inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther. 2004 ; 14 (suppl 1). 74-78
94. Zedtwitz-Liebenstein K, Wenisch C, Patruta S, et al. Omperazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med. 2002 ; 30 (5). 1118-1122
95. Heidelbaugh JJ, Kim AH, Chang R, et al. Overutilization of proton-pump inhibitors: what the clinician needs to know. Ther Adv Gastroenterol. 2012 ; 5 (4). 219-232
96. Garey KW, Jiang Z, Ghantoji S, et al. A common polymorphism in the interleukin-8 gene promoter is associated with an increased risk for recurrent Clostridium difficile infection. Clin Infect Dis. :
97. Kyne L, Warny M, Qamar A, et al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med. 2000 ; 342 (6). 390-397
98. Kyne L, Warny M, Qamar A, et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhea. Lancet. 2001 ; 357 (9251). 189-193
99. Jian ZD, DuPont HL, Garey, et al. A common polymorphism in the interleukin 8 gene promoter is associated with Clostridium difficile diarrhea. Am J Gastroenterol. 2006 ; 101 (5). 1112-1116
100. Chopra T, Alangaden GJ, Chandrasekar P.. Clostridium difficile infection in cancer patients and hematopoietic stem cell transplant recipients. Expert Rev Anti Infect Ther. 2010 ; 8 (10). 1113-1119
101. Eddi R, Malik MN, Shakrov R, et al. Chronic kidney disease as a risk factor for Clostridium difficile infection. Nephrology. :
102. Raines DL, Lopez FA.. Clostridium difficile infection in non-HIV-immunocompromised patients and in HIV-infected patients. Curr Gastroenterol Rep. 2011 ; 13 (4). 344-350
103. Boutros M, Al-Shaibi M, Chan G, et al. Clostridium difficile colitis: increasing incidence, risk factors, and outcomes in solid organ transplant recipients. Transplantation. 2012 ; 93 (10). 1051-1057
104. Dubberke ER, Riddle DJ. Clostridium difficile in solid organ transplant recipients. Am J Transplant. 2009 ; 9 (suppl 4). S35 - S40
105. Navaneethan U, Venkatesh PGK, Shen B.. Clostridium difficile infection in inflammatory bowel disease: understanding the evolving relationship. World J Gastroenterol. 2010 ; 16 (39). 4892-4904
106. Kutty PK, Wood CW, Sena AC, et al. Risk factors for and estimated incidence of community-associated Clostridium difficile infection, North Carolina, USA. Emerg Infect Dis. 2010 ; 16 (2). 197-204
107. Dumyati G, Stevens V, Hannett GE, et al. Community-associated Clostridium difficile infections, Monroe county, New York, USA. Emerg Infect Dis. 2012 ; 18 (3). 392-400
108. Rogers MA, Greene MT, Saint S, et al. Higher rates of Clostridium difficile infection among smokers. PLoS One. 2012 ; 7 (7). e42091
109. Pépin J, Gonazales M, Valiquette L. Risk of secondary cases of Clostridium difficile infection among household contacts of index cases. J Infect Dis. 2012 ; 64 (4). 387-390
110. Gould LH, Limbago B.. Clostridium difficile in food and domestic animals: a new foodborne pathogen?. Clin Infect Dis. 2010 ; 51 (5). 577-582
111. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo controlled trial of saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA. 1994 ; 271 (24). 1913-198
112. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol. 2002 ; 97 (7). 1769-1775
113. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Eng J Med. 2013 ; 368 (5). 407-415
114. McDonald LC, Coignard B, Dubberke E, et al. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol. 2007 ; 28 (2). 140-145
115. Fitzpatrick F, Barbut F. Breaking the cycle of recurrent Clostridium difficile infections. Clin Microbiol Infect. 2012 ; 18 (suppl 6). 2-4
116. Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile Infections. Am J Gastroenterol. 2013 ; 108 (4). 478-498
117. Crobach MJ, Dekkers OM, Wilcox MH, et al. European society of clinical microbiology and infectious diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin Microbiol Infect. 2009 ; 15 (12). 1053-1066
118. Fong KS, Fatica C, Hall G, et al. Impact of PCR testing for Clostridium difficile on incident rates and potential on public reporting: is the playing field level?. Infect Control Hosp Epidemiol. 2011 ; 32 (9). 932-933
119. Wilcox MH. Overcoming barriers to effective recognition and diagnosis of Clostridium difficile infection. Clin Microbiol Infect. 2012 ; 18 (suppl 6). 13-20
120. Longtin Y, Trottier S, Brochu G, et al. Impact of the type of diagnostic assay on Clostridium difficile infection and complication rates in a mandatory reporting program. Clin Infect Dis. 2013 ; 56 (1). 67-73
121. Kaltsas A, Simon M, Unruh LH, et al. Clinical and laboratory characteristics of Clostridium difficile infection in patients with discordant diagnostic test results. J Clin Microbiol. 2012 ; 50 (4). 1303-1307